The frequency of cancer in France in 2006, mortality trends since 1950, incidence trends since 1980 and analysis of the discrepancies between these trends;La fréquence des cancers en France en 2006 et les évolutions de la mortalité depuis 1950 et de l'incidence depuis 1980

Bulletin du Cancer

Volumn 96, Issue 1, 2009, Pages 51-57

  GueRin S ^a   Doyon, F ^a   Hill, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast; Cancer; Incidence; Lung; Mortality; Prostate

Indexed keywords

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; DEMOGRAPHY; HUMAN; LUNG CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SEX DIFFERENCE; ARTICLE; BREAST TUMOR; FEMALE; FRANCE; INCIDENCE; MALE; MORTALITY; NEOPLASM; PROSTATE TUMOR;

BREAST NEOPLASMS; FEMALE; FRANCE; HUMANS; INCIDENCE; MALE; MORTALITY; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 61549096055     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0795     Document Type: Review

References (9)

1. Hill C, Benhamou E, Doyon F, Flamand R. Évolution de la mortalité par cancer en France de 1950 à 1985. Paris : Inserm, 1989.
2. Hill C, Benhamou E, Auquier A. Comment mesurer le risque de cancer du sein dans une population ? Bull Cancer 1994 ; 81 : 785-7.
3. Hill C, Doyon F. Mortalité par cancer en France : le nombre de décès augmente, mais le risque de décès par cancer diminue. Presse Med 2007 ; 36 : 383-7.
4. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Dela-fosse P, et al. (2008). Cancer incidence and mortality in France over the period 1980-2005. *Rev Epidemiol Sante Publique. 2008 Jun ;56 (3) : 159-75. Epub 2008 Jun 10. *Detailed results and comments [online] http ://www.invs.sante.fr/surveillance/cancers/estirnations-cancers/default.htm.
5. Telesca D, Etzioni R, Gulati R. Estimating lead-time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008 ; 64(1) : 10-9.
6. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening : lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 ; 94(13) : 981-90.
7. Pad E, Miccinesi G, Puliti D, Baldazzi P, De Lisi V, Falcini F, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead-time. A service screening study in Italy. Breast Cancer Res 2006 ; 8(6) : R68.
8. Zahl PH, Mæhíen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008 ; 168(21) : 2311-6.
9. Zackrisson S, Andersson I, Janzon L, Manjer J, Game )P. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mam-mographic screening trial : follow-up study. BMJ 2006 ; 332(7543) : 689-92.